Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

The new Mercedes-Benz eEconic is a first of its kind all-electric tanker truck helping to reduce emissions at Airbus’ Donauwörth facility by pumping sustainable aviation fuel (SAF) into new ...

View all 2021 Honda Civic specs. The good: The bad: The sedan has a standard 158-horsepower, 2.0-liter four-cylinder engine and an optional 174-hp, turbocharged 1.5-liter four-cylinder.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

These approvals allow marketing of these KEYTRUDA regimens for these indications in all 27 EU member states, as well as Iceland, Liechtenstein, Norway and Northern Ireland. Timing for commercial ...

One of the major trials for efti is the Phase II TACTI-002 trial, conducted in partnership with Merck, which produces the immunotherapy drug KEYTRUDA. KEYTRUDA works by blocking a protein called PD-1 ...

According to McKinsey, the medical industry’s overall profits are projected to grow at a compound annual growth rate (CAGR) of 4%, increasing from $654 billion in 2021 to $790 billion by 2026.